Esmolol
As of the edition of 20 October 2026, Esmolol is a small molecule: marketed, first approved in 1988 (US); acts on ADRB1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2011
- Kind
- Small molecule
- Brand name
- Brevibloc
- First approved
- 15 August 1988 (US)
- Approvals on record
- 11 in 4 regions
- Holder of the most recent approval
- Hq Specialty Pharma; 3 holders in all
- Withdrawn from market
- 1 January 2010 (in some regions)
- Registered trials
- 59, 9 stopped early
- Disease areas
- Heart and blood vessels; Infections; Nervous system; Injuries; Mental health; Hormones
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Esmolol.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ADRB1 | Beta-1 adrenergic receptor | P08588 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 19 | 9 | 3 | 2 |
| Phase 2 | 15 | 7 | 1 | 1 |
| Phase 3 | 6 | 1 | 2 | 2 |
| Phase 4 | 19 | 6 | 3 | 4 |
| All trials | 59 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Baxter Healthcare | Applicant and Acquired holder | 1996 to now |
| Hq Specialty Pharma | Later holder | 2016 to now |